IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
AU6776196A
(en)
*
|
1995-08-16 |
1997-03-12 |
Eli Lilly And Company |
Potentiation of serotonin response
|
IN182588B
(forum.php)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
IN186677B
(forum.php)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
WO2001080845A2
(en)
*
|
2000-04-24 |
2001-11-01 |
Aryx Therapeutics |
(2-aminoethyl) oxime derivatives for the treatment of depression
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
CN103288815A
(zh)
*
|
2001-10-12 |
2013-09-11 |
阿泽范药品公司 |
β-内酰胺后叶加压素V1a拮抗剂
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
CA2532207A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
JP5646126B2
(ja)
|
2003-12-11 |
2014-12-24 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
WO2005108683A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2601709C
(en)
|
2005-03-22 |
2017-02-14 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids
|
CN101175740A
(zh)
|
2005-04-22 |
2008-05-07 |
惠氏公司 |
二氢苯并呋喃衍生物和其用途
|
CA2604759A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Dihydrobenzofuran derivatives and uses thereof
|
AU2006239897A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
US7368477B2
(en)
|
2005-04-22 |
2008-05-06 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof
|
AU2006269231A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
KR101521405B1
(ko)
*
|
2005-07-19 |
2015-05-18 |
아제반 파마슈티칼스, 인코퍼레이티드 |
베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신 길항물질
|
WO2007014124A2
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
MX2008012094A
(es)
*
|
2006-03-24 |
2008-10-03 |
Wyeth Corp |
Nuevas combinaciones terapeuticas para el tratamiento de la depresion.
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
US20080171750A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation Of Neurogenesis With Use of Modafinil
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
SMT201900392T1
(it)
|
2009-10-23 |
2019-09-09 |
Janssen Pharmaceutica Nv |
Ottaidropirrolo[3,4-c]pirroli disostituiti come modulatori del recettore di orexina
|
EP2509596B1
(en)
|
2009-12-08 |
2019-08-28 |
Case Western Reserve University |
Gamma aminoacids for treating ocular disorders
|
EP3351104B1
(en)
|
2010-07-01 |
2020-12-09 |
Azevan Pharmaceuticals, Inc. |
Compounds for use in the treatment of intermittent explosive disorder
|
MX2013010598A
(es)
|
2011-03-17 |
2014-01-08 |
Lupin Ltd |
Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo.
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
IN2013MU01290A
(forum.php)
*
|
2013-04-03 |
2015-04-10 |
Zcl Chemicals Ltd |
|
WO2015118365A1
(en)
|
2014-02-07 |
2015-08-13 |
Mta Támogatott Kutatócsoportok Irodája |
Novel use of sigma-1 receptor agonist compounds
|
NZ724718A
(en)
|
2014-03-28 |
2023-04-28 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
IL319248A
(en)
|
2016-03-10 |
2025-04-01 |
Janssen Pharmaceutica Nv |
Methods for treating depression using orexin-2 receptor antagonists
|
DK3544420T3
(da)
|
2016-11-24 |
2022-09-05 |
Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag |
Anvendelse af sammensætninger til organ-/vævskonservering
|
WO2019055913A1
(en)
|
2017-09-15 |
2019-03-21 |
Azevan Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
|
KR20220049526A
(ko)
|
2019-07-19 |
2022-04-21 |
바이오엑셀 테라퓨틱스 인코포레이티드 |
비-진정성 덱스메데토미딘 치료 양생법
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|